Osiris Therapeutics, Inc. to Receive Milestone Payment from JCR Pharmaceuticals

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading stem cell therapeutic company, announced today that it will receive a $500,000 milestone payment under its collaboration agreement with JCR Pharmaceuticals. The milestone payment was triggered when JCR Pharmaceuticals filed a Clinical Trial Notice to the Pharmaceuticals and Medical Devices Agency in Japan to initiate a clinical trial in patients with Graft vs. Host Disease (GvHD).